BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.170
-0.030 (-2.50%)
At close: Jul 6, 2026, 4:00 PM EDT
1.172
+0.002 (0.13%)
After-hours: Jul 6, 2026, 7:52 PM EDT
BioCardia Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
13.31M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
| Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
| Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
| Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
| Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
| Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
| Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
| Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
| Dec 31, 2011 | 12.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Cyclerion Therapeutics | 1.99M |
| BioLineRx | 1.40M |
| Lexaria Bioscience | 368.00K |
| Cocrystal Pharma | 225.00K |
BCDA News
- 18 days ago - BioCardia issues letter to shareholders on 2026 priorities - TheFly
- 18 days ago - BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities - GlobeNewsWire
- 4 weeks ago - BioCardia Announces $4.4 Million Financing - GlobeNewsWire
- 4 weeks ago - FDA confirms CardiAMP Heart Failure II Trial may support premarket approval - TheFly
- 4 weeks ago - FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF - GlobeNewsWire
- 6 weeks ago - BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency - GlobeNewsWire
- 6 weeks ago - BioCardia Transcript: A.G.P.'s Annual Virtual Healthcare Conference - Transcripts
- 7 weeks ago - BioCardia Earnings Call Transcript: Q1 2026 - Transcripts